Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA OK's Onivyde In Pancreatic Cancer; Warnings Smack Merrimack

This article was originally published in Scrip

Executive Summary

Merrimack Pharmaceuticals Inc. won the FDA's approval on Oct. 22 to market Onivyde (irinotecan liposome injection), an topoisomerase inhibitor, as a treatment in combination with fluorouracil (5-FU) and leucovorin for patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.


Related Content

Merrimack's Slow Ramp-up For Onivyde Prompts Cutbacks


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts